325 related articles for article (PubMed ID: 17651855)
21. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers.
Ungaro F; d'Angelo I; Coletta C; d'Emmanuele di Villa Bianca R; Sorrentino R; Perfetto B; Tufano MA; Miro A; La Rotonda MI; Quaglia F
J Control Release; 2012 Jan; 157(1):149-59. PubMed ID: 21864595
[TBL] [Abstract][Full Text] [Related]
22. Design of surface-modified poly(D,L-lactide-co-glycolide) nanoparticles for targeted drug delivery to bone.
Choi SW; Kim JH
J Control Release; 2007 Sep; 122(1):24-30. PubMed ID: 17628158
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticles as drug delivery agents specific for CNS: in vivo biodistribution.
Vergoni AV; Tosi G; Tacchi R; Vandelli MA; Bertolini A; Costantino L
Nanomedicine; 2009 Dec; 5(4):369-77. PubMed ID: 19341816
[TBL] [Abstract][Full Text] [Related]
24. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
25. PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier.
Fornaguera C; Dols-Perez A; Calderó G; García-Celma MJ; Camarasa J; Solans C
J Control Release; 2015 Aug; 211():134-43. PubMed ID: 26057857
[TBL] [Abstract][Full Text] [Related]
26. Chapter 3 - Colloidal systems for CNS drug delivery.
Costantino L; Tosi G; Ruozi B; Bondioli L; Vandelli MA; Forni F
Prog Brain Res; 2009; 180():35-69. PubMed ID: 20302828
[TBL] [Abstract][Full Text] [Related]
27. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB).
Ulbrich K; Hekmatara T; Herbert E; Kreuter J
Eur J Pharm Biopharm; 2009 Feb; 71(2):251-6. PubMed ID: 18805484
[TBL] [Abstract][Full Text] [Related]
28. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain.
Michaelis K; Hoffmann MM; Dreis S; Herbert E; Alyautdin RN; Michaelis M; Kreuter J; Langer K
J Pharmacol Exp Ther; 2006 Jun; 317(3):1246-53. PubMed ID: 16554356
[TBL] [Abstract][Full Text] [Related]
29. Development and evaluation of novel biodegradable microspheres based on poly(d,l-lactide-co-glycolide) and poly(epsilon-caprolactone) for controlled delivery of doxycycline in the treatment of human periodontal pocket: in vitro and in vivo studies.
Mundargi RC; Srirangarajan S; Agnihotri SA; Patil SA; Ravindra S; Setty SB; Aminabhavi TM
J Control Release; 2007 May; 119(1):59-68. PubMed ID: 17331611
[TBL] [Abstract][Full Text] [Related]
30. Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain.
Kreuter J; Hekmatara T; Dreis S; Vogel T; Gelperina S; Langer K
J Control Release; 2007 Mar; 118(1):54-8. PubMed ID: 17250920
[TBL] [Abstract][Full Text] [Related]
31. PLGA nanoparticles for oral delivery of cyclosporine: nephrotoxicity and pharmacokinetic studies in comparison to Sandimmune Neoral.
Italia JL; Bhatt DK; Bhardwaj V; Tikoo K; Kumar MN
J Control Release; 2007 Jun; 119(2):197-206. PubMed ID: 17399839
[TBL] [Abstract][Full Text] [Related]
32. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
33. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carriers for nasal gene delivery.
Csaba N; Sánchez A; Alonso MJ
J Control Release; 2006 Jun; 113(2):164-72. PubMed ID: 16759732
[TBL] [Abstract][Full Text] [Related]
34. Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution.
Yin Y; Chen D; Qiao M; Wei X; Hu H
J Control Release; 2007 Oct; 123(1):27-38. PubMed ID: 17728000
[TBL] [Abstract][Full Text] [Related]
35. Drug delivery to the CNS and polymeric nanoparticulate carriers.
Costantino L
Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma.
Lee JS; An TK; Chae GS; Jeong JK; Cho SH; Lee HB; Khang G
Eur J Pharm Biopharm; 2005 Jan; 59(1):169-75. PubMed ID: 15567315
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
38. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport.
Tosi G; Vilella A; Chhabra R; Schmeisser MJ; Boeckers TM; Ruozi B; Vandelli MA; Forni F; Zoli M; Grabrucker AM
J Control Release; 2014 Mar; 177():96-107. PubMed ID: 24417968
[TBL] [Abstract][Full Text] [Related]
39. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives.
Mundargi RC; Babu VR; Rangaswamy V; Patel P; Aminabhavi TM
J Control Release; 2008 Feb; 125(3):193-209. PubMed ID: 18083265
[TBL] [Abstract][Full Text] [Related]
40. Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats.
Sharma G; Italia JL; Sonaje K; Tikoo K; Ravi Kumar MN
J Control Release; 2007 Mar; 118(1):27-37. PubMed ID: 17258836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
